Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Isotechnika Pharma Inc IPHAF

GREY:IPHAF - Post Discussion

Isotechnika Pharma Inc > POSITIVE NEWS? JUST MORE PR. BS. , DEFLECT
View:
Post by ISAloser247 on Dec 06, 2012 4:59pm

POSITIVE NEWS? JUST MORE PR. BS. , DEFLECT

FROM THE CON!  The Nicams "WORK SYNERGISTICALLY" with inteferon,  NOT ON ITS" OWN!!!!  HOW MANY "RESEARCHERS, SCIENTISTS" are at ISA?  MOST EMPLOYEES OF ISA ARE PAPER PUSHERS!!!! FILLING OUT LEGAL DOCUMENTS,  "MAKIN' COPIES" !   THERE IS  ABSOLUTELY NO ONE, THAT HAS ANY RESPECT FOR DR> BUNDY, IN THE MEDICAL COMMUNITY,  HE APPEARED ON THE HOME SHOPPING NETWORK,  SNAKEOILING VOCLOSPORIN,  HE IS GOING TO SAVE THE WORLD FROM HEPATITIS?   I DO RECALL THAT A DR. TYRELL,  ALSO FROM THE U of A, ALSO WITH A BANKRUPT BIO-COMPANY,  DISCOVERED, WAS HIGHLY DISTINGUISHED, AWARDED WITH FINDING A VACINE AGAINST HEPATITIS!   MAYBE  KRANK CAN HAVE HIS SAY WHEN ISA FINALLY HAS A MARKETABLE PRODUCT,  MAKING SALES,  RETURNING SOME VALUE FOR SHAREHOLDERS--------INSTEAD OF JUST , IRRELEVANT---PROMISING-----BU**SH**!
Comment by isatheone on Dec 07, 2012 8:50am
"The Nicams "WORK SYNERGISTICALLY" with inteferon,  NOT ON ITS" OWN!!!! " NOT TRUE!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! FROM THE PRESS RELEASE: Results demonstrate that the NICAMs are highly active (low nanomolar potency) against HCV genotypes, 1 and 2, which represent approximately 85% of the HCV infections globally ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities